First human test for new kidney disease pill
NCT ID NCT06428825
Summary
This early-stage study tested the safety of a new oral drug, BAY3283142, in people with high blood pressure and chronic kidney disease. The drug is designed to relax blood vessels. For 10 weeks, 75 participants took either the drug or a placebo pill, and researchers monitored them for side effects. The goal was to gather safety information to help develop the drug for future kidney disease treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, State of Berlin, 13627, Germany
-
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit
Mannheim, Baden-Wurttemberg, 68167, Germany
Conditions
Explore the condition pages connected to this study.